

Felice Iasevoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5770491/publications.pdf>

Version: 2024-02-01

125
papers

3,592
citations

101543

36
h-index

168389

53
g-index

131
all docs

131
docs citations

131
times ranked

5152
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. <i>Neuron</i> , 2015, 87, 549-562.	8.1	168
2	Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. <i>CNS Drugs</i> , 2015, 29, 773-799.	5.9	131
3	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, 129.	2.8	124
4	Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 34-48.	4.8	120
5	Glutamatergic Postsynaptic Density Protein Dysfunctions in Synaptic Plasticity and Dendritic Spines Morphology: Relevance to Schizophrenia and Other Behavioral Disorders Pathophysiology, and Implications for Novel Therapeutic Approaches. <i>Molecular Neurobiology</i> , 2014, 49, 484-511.	4.0	116
6	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. <i>Frontiers in Psychiatry</i> , 2016, 7, 138.	2.6	115
7	An update of safety of clinically used atypical antipsychotics. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1329-1347.	2.4	112
8	Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. <i>Psychological Medicine</i> , 2021, 51, 1054-1056.	4.5	104
9	Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. <i>Current Drug Targets</i> , 2015, 16, 1094-1106.	2.1	89
10	The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. <i>Psychopharmacology Bulletin</i> , 2003, 37, 51-83.	0.0	75
11	Scaffolding Proteins of the Post-synaptic Density Contribute to Synaptic Plasticity by Regulating Receptor Localization and Distribution: Relevance for Neuropsychiatric Diseases. <i>Neurochemical Research</i> , 2013, 38, 1-22.	3.3	70
12	Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. <i>Psychiatry Research</i> , 2013, 210, 387-395.	3.3	69
13	The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12458-12483.	4.1	66
14	Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1111-1130.	4.1	66
15	Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: Role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 46, 1-12.	4.8	61
16	The relationship between emotional regulation and eating behaviour: a multidimensional analysis of obesity psychopathology. <i>Eating and Weight Disorders</i> , 2017, 22, 105-115.	2.5	61
17	Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. <i>European Journal of Pharmacology</i> , 2012, 682, 1-11.	3.5	60
18	Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. <i>International Journal of Molecular Sciences</i> , 2017, 18, 135.	4.1	57

#	ARTICLE	IF	CITATIONS
19	The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview. <i>Current Pharmaceutical Design</i> , 2013, 19, 6367-6374.	1.9	57
20	A Systematized Review of Atypical Antipsychotics in Pregnant Women. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e477-e489.	2.2	55
21	A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 35-44.	1.4	53
22	Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder. <i>Neuropharmacology</i> , 2017, 121, 179-194.	4.1	52
23	Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 125-130.	1.7	50
24	Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1885.	2.2	47
25	Affective temperaments are associated with specific clusters of symptoms and psychopathology: A cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. <i>Journal of Affective Disorders</i> , 2013, 151, 540-550.	4.1	46
26	Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder. <i>Archives of Suicide Research</i> , 2017, 21, 100-112.	2.3	46
27	The acute and chronic effects of combined antipsychoticâ€“mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 184-197.	4.8	44
28	Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. <i>Psychopharmacology</i> , 2010, 212, 329-344.	3.1	43
29	Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1113.	2.2	43
30	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in â€œreal-world,â€“everyday clinical practice. <i>CNS Spectrums</i> , 2017, 22, 342-347.	1.2	43
31	Dopamine receptor subtypes contribution to Homer1a induction: Insights into antipsychotic molecular action. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 813-821.	4.8	42
32	The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment. <i>Current Neuropharmacology</i> , 2014, 12, 219-238.	2.9	42
33	Pattern of acute induction of <i>Homer1a</i> gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. <i>Journal of Psychopharmacology</i> , 2011, 25, 875-887.	4.0	40
34	Ketamine-related expression of glutamatergic postsynaptic density genes: Possible implications in psychosis. <i>Neuroscience Letters</i> , 2007, 416, 1-5.	2.1	39
35	Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and â€œtherapeutic sensation seekingâ€“in response towards subjective intolerance to pain. <i>Journal of Affective Disorders</i> , 2013, 151, 596-604.	4.1	39
36	Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. <i>Psychiatry Research</i> , 2010, 177, 255-260.	3.3	38

#	ARTICLE	IF	CITATIONS
37	The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment. <i>Journal of Psychopharmacology</i> , 2014, 28, 505-526.	4.0	38
38	Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study. <i>Comprehensive Psychiatry</i> , 2015, 58, 82-87.	3.1	36
39	Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 719-728.	4.1	35
40	Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 240.	2.0	35
41	Imaging brain gene expression profiles by antipsychotics: Region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. <i>European Neuropsychopharmacology</i> , 2013, 23, 1516-1529.	0.7	34
42	The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 252-264.	1.4	32
43	Antipsychotic and antidepressant co-treatment: Effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. <i>Brain Research Bulletin</i> , 2009, 79, 123-129.	3.0	31
44	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 349.	4.1	30
45	Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 174-178.	2.0	28
46	Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: Insights for psychosis treatment. <i>European Neuropsychopharmacology</i> , 2015, 25, 566-582.	0.7	27
47	Inflammatory markers and suicidal attempts in depressed patients: A review. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 583-594.	2.1	27
48	Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 356-366.	4.8	27
49	Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 369.	2.6	25
50	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2016, 22, 5144-5162.	1.9	25
51	Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review. <i>Current Clinical Pharmacology</i> , 2013, 8, 256-264.	0.6	25
52	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 65-92.	1.4	25
53	Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2014, 8, 30-37.	0.6	24
54	Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 29-41.	4.8	24

#	ARTICLE	IF	CITATIONS
55	Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs. <i>Frontiers in Psychiatry</i> , 2018, 9, 553.	2.6	24
56	The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 289-303.	6.1	24
57	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. <i>BioMed Research International</i> , 2017, 2017, 1-17.	1.9	23
58	S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study. <i>Scientific World Journal</i> , The, 2013, 2013, 1-5.	2.1	20
59	Prevalence and clinical features associated to bipolar disorderâ€“migraine comorbidity: a systematic review. <i>Comprehensive Psychiatry</i> , 2015, 56, 1-16.	3.1	20
60	Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1419-1444.	2.4	19
61	Clozapineâ€™s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia. , 2022, 236, 108236.		19
62	The Interface between Neuroscience and Neuro-Psychoanalysis: Focus on Brain Connectivity. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 20.	2.0	18
63	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 483-495.	2.8	18
64	Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 299-314.	4.8	17
65	Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 795-827.	6.1	17
66	Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia. <i>Journal of Psychopharmacology</i> , 2017, 31, 406-417.	4.0	16
67	Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. <i>Journal of Affective Disorders</i> , 2018, 234, 131-138.	4.1	16
68	Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment. <i>European Journal of Pharmacology</i> , 2013, 718, 502-523.	3.5	15
69	MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamineâ€™Glutamate Interaction at the Postsynaptic Density. <i>New Avenues for Antipsychotic Treatment Under a Theranostic Perspective. Molecular Neurobiology</i> , 2015, 52, 1771-1790.	4.0	15
70	Obsessive-Compulsive Aspects and Pathological Gambling in an Italian Sample. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	14
71	Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1269-1278.	0.7	14
72	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). <i>Journal of Affective Disorders</i> , 2015, 178, 112-120.	4.1	14

#	ARTICLE	IF	CITATIONS
73	Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 24-38.	4.8	14
74	Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients. <i>Schizophrenia Research</i> , 2018, 202, 217-225.	2.0	14
75	Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia. <i>Microbial Biotechnology</i> , 2022, 16, 352-362.	1.7	14
76	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 317-321.	1.7	14
77	Cerebellar Transcranial Direct Current Stimulation in Children with Autism Spectrum Disorder: A Pilot Study on Efficacy, Feasibility, Safety, and Unexpected Outcomes in Tic Disorder and Epilepsy. <i>Journal of Clinical Medicine</i> , 2022, 11, 143.	2.4	14
78	CHD2 mutations: Only epilepsy? Description of cognitive and behavioral profile in a case with a new mutation. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 51, 186-189.	2.0	13
79	Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: Translational inference from a postsynaptic density immediate-early gene-based network analysis. <i>Behavioural Brain Research</i> , 2021, 404, 113160.	2.2	13
80	The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: An emerging molecular "Lego" in the pathophysiology of psychiatric disorders. A systematic review and translational insight. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104596.	6.1	12
81	The role of melatonin in mood disorders. <i>ChronoPhysiology and Therapy</i> , 0, , 65.	0.5	11
82	D-aspartate dysregulation in <i>DDo^{+/+}</i> mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 62, 35-43.	4.8	11
83	Glutamatergic postsynaptic density in early life stress programming: Topographic gene expression of mGlu5 receptors and Homer proteins. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 96, 109725.	4.8	11
84	Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses. <i>Psychiatry Research</i> , 2018, 269, 481-493.	3.3	10
85	Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110493.	4.8	9
86	The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions. <i>Current Molecular Pharmacology</i> , 2014, 6, 149-155.	1.5	8
87	Clozapine-Related Pericarditis During Titration Phase in a Patient With Resistant Schizophrenia and Concomitant Valproate Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 649-651.	1.4	8
88	Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients. <i>Journal of Affective Disorders</i> , 2018, 228, 118-124.	4.1	8
89	The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5555.	4.1	8
90	The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: A putative link between metabolism and an animal model of psychosis. <i>Journal of Neuroscience Research</i> , 2012, 90, 1756-1767.	2.9	7

#	ARTICLE	IF	CITATIONS
91	Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. <i>European Neuropsychopharmacology</i> , 2018, 28, 538-559.	0.7	7
92	Creativity and psychiatric illness: A functional perspective beyond chaos. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 91-100.	4.8	7
93	Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases. <i>Frontiers in Psychiatry</i> , 2020, 11, 438.	2.6	7
94	Cotard's Syndrome after breast surgery successfully treated with aripiprazole augmentation of escitalopram: a case report. <i>Rivista Di Psichiatria</i> , 2015, 50, 95-8.	0.6	7
95	Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study. <i>ISRN Pharmacology</i> , 2014, 2014, 1-9.	1.6	6
96	Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients. <i>Psychiatry Research</i> , 2017, 249, 159-166.	3.3	5
97	The effects of sustained COVID-19 emergency and restrictions on the mental health of subjects with serious mental illness: A prospective study. <i>Journal of Community Psychology</i> , 2023, 51, 154-167.	1.8	5
98	Predicting the Severity of Lockdown-Induced Psychiatric Symptoms with Machine Learning. <i>Diagnostics</i> , 2022, 12, 957.	2.6	3
99	Striatal expression of Homer1a is affected by genotype but not dystonic phenotype of tottering mice: A model of spontaneously occurring motor disturbances. <i>Neuroscience Letters</i> , 2011, 503, 176-180.	2.1	2
100	Editorial: Neurobiology, Clinical Course, and Therapeutic Approaches of Treatment-Resistant Schizophrenia: Toward an Integrated View. <i>Frontiers in Psychiatry</i> , 2019, 10, 870.	2.6	2
101	Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?. <i>Minerva Psichiatria</i> , 2017, 58, .	0.3	1
102	F234. TYPICAL AND ATYPICAL ANTIPSYCHOTICS' D2R AFFINITY AND DOSES INFLUENCES POSTSYNAPTIC DENSITY BY MODULATING THE SPATIAL EXPRESSION OF HOMER1A A GENE HIGHLY IMPLICATED IN SYNAPTIC PLASTICITY AND PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S313-S313.	4.3	1
103	Psychological Impact of COVID-19 national lockdown measures on transgender people in Italy: The PICARD study. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
104	Pharmacotherapy to prevent the onset of depression following traumatic brain injury. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 255-262.	1.8	1
105	Alexithymia and Breast Cancer Surgery: A Systematic Review. <i>British Journal of Medicine and Medical Research</i> , 2016, 15, 1-11.	0.2	1
106	Poster #110 USING A TRANSLATIONAL APPROACH TO STUDY BEHAVIORAL DISORDERS' PATHOPHYSIOLOGY: DOPAMINE SYSTEM IS AFFECTED IN A GLUTAMATERGIC ANIMAL MODEL OF PSYCHOSIS. <i>Schizophrenia Research</i> , 2012, 136, S131.	2.0	0
107	Poster #9 ANTAGONISTS AT N-METHYL-D-ASPARTATE RECEPTOR (NMDA-R) WITH DIFFERENT CLINICAL PROFILE AFFECT DIFFERENTLY THE TRANSCRIPTS OF CONSTITUTIVE AND INDUCIBLE EARLY GENES AT POSTSYNAPTIC DENSITY. <i>Schizophrenia Research</i> , 2012, 136, S188.	2.0	0
108	P.3.c.008 Immediate early and constitutive genes expression in antipsychotic switching paradigm: from clinical practice to animal model. <i>European Neuropsychopharmacology</i> , 2014, 24, S519.	0.7	0

#	ARTICLE	IF	CITATIONS
109	PM437. Spatial and temporal modulation of Homer1a gene expression at the post-synaptic density is related to D2R affinity and dose of antipsychotics: translational considerations for schizophrenia treatment strategies.. International Journal of Neuropsychopharmacology, 2016, 19, 59-59.	2.1	0
110	P.1.009 Effects of caffeine, nicotine and their combination with haloperidol on PSD molecules: relevance to psychiatric diseases. European Neuropsychopharmacology, 2016, 26, S10-S11.	0.7	0
111	Chronobiology of Mood Disorders. , 2016, , 273-295.		0
112	Psychiatric patients show different coping styles during aggression compared to controls. European Psychiatry, 2017, 41, S745-S745.	0.2	0
113	Impact of an Intervention of Neuro-cognitive Rehabilitation in Treatment Resistant Schizophrenia (TRS) Compared to Schizophrenia Responder Patients. European Psychiatry, 2017, 41, S266-S267.	0.2	0
114	F233. NEGATIVE SYMPTOMS ARE INDEPENDENT MODERATOR FACTORS OF TREATMENT RESISTANT SCHIZOPHRENIA EFFECTS ON MULTIPLE CLINICAL, PSYCHOPATHOLOGICAL, COGNITIVE AND PSYCHOSOCIAL VARIABLES. Schizophrenia Bulletin, 2018, 44, S312-S313.	4.3	0
115	T226. CLINICAL PREDICTORS OF FUNCTIONAL CAPACITY IN TREATMENT RESISTANT SCHIZOPHRENIA PATIENTS: COMPARISON WITH RESPONDER PATIENTS, ROLE OF NEGATIVE SYMPTOMS, PROBLEM SOLVING DYSFUNCTIONS, AND NEUROLOGICAL SOFT SIGNS. Schizophrenia Bulletin, 2018, 44, S204-S204.	4.3	0
116	S228. TOWARD EARLY DETECTION OF TREATMENT RESISTANT SCHIZOPHRENIA: PREDICTIVE INFORMATION ON NON-RESPONSE TO ANTIPSYCHOTICS BY EVALUATION OF A FEW CLINICAL FACTORS: A STUDY BY ROC CURVE ANALYSIS AND CONFIRMATORY MULTIVARIATE ANALYSIS. Schizophrenia Bulletin, 2018, 44, S414-S415.	4.3	0
117	Duration of antipsychotic treatment and doses/receptor profile modulate early gene expression throughout rat brain regions. European Neuropsychopharmacology, 2019, 29, S610-S611.	0.7	0
118	M139. DIFFERENTIAL PATTERNS OF BRAIN METABOLISM IN STABILIZED, ACTIVELY SYMPTOMATIC TREATMENT RESISTANT VS. TREATMENT RESPONDER SCHIZOPHRENIA PATIENTS: A STUDY BY 18F-FDG-POSITRON EMISSION TOMOGRAPHY AND STRUCTURAL 3T MRI. Schizophrenia Bulletin, 2020, 46, S188-S188.	4.3	0
119	M170. GENETIC CHARACTERIZATION OF A COHORT OF PATIENTS AFFECTED BY SCHIZOPHRENIA. THE ROLE FOR RARE STRUCTURAL VARIANTS IN MODULATING TREATMENT RESISTANT ENDOPHENOTYPES: PRELIMINARY DATA. Schizophrenia Bulletin, 2020, 46, S201-S201.	4.3	0
120	S202. PROXIMAL AND DISTAL FACTORS ASSOCIATED WITH CLOZAPINE EXPOSURE IN A SAMPLE OF TREATMENT RESISTANT AND TREATMENT RESPONSIVE SCHIZOPHRENIA PATIENTS. Schizophrenia Bulletin, 2020, 46, S115-S115.	4.3	0
121	O9.4. RELATIONSHIPS BETWEEN AGE AT ONSET OF PSYCHOTIC SYMPTOMS AND POOR RESPONSE TO ANTIPSYCHOTICS IN A SAMPLE OF TRS/NON-TRS PATIENTS. Schizophrenia Bulletin, 2020, 46, S22-S22.	4.3	0
122	S205. A TRANSLATIONAL HOMER 1A-BASED NETWORK APPROACH: IMAGING HOW HALOPERIDOL MODULATES GLUTAMATE SYSTEM FUNCTIONAL CONNECTIVITY. Schizophrenia Bulletin, 2020, 46, S116-S117.	4.3	0
123	Psychological distress in patients with hypocortisolism during mass quarantine for Covid-19 epidemic in Italy. Endocrine Abstracts, 0, , .	0.0	0
124	Differential Adaptive Changes in Dopaminergic System by Acute vs. Subchronic Ketamine: Relevance for Psychosis Pathophysiology and Treatment. Current Signal Transduction Therapy, 2013, 8, 119-128.	0.5	0
125	S-Adenosyl-L-Methionine for Major Depressive Disorder. , 2016, , 847-854.		0